CN117598247A - 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 - Google Patents
咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 Download PDFInfo
- Publication number
- CN117598247A CN117598247A CN202311848219.2A CN202311848219A CN117598247A CN 117598247 A CN117598247 A CN 117598247A CN 202311848219 A CN202311848219 A CN 202311848219A CN 117598247 A CN117598247 A CN 117598247A
- Authority
- CN
- China
- Prior art keywords
- propionic acid
- ulcerative colitis
- application
- animal model
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 16
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 16
- 238000010171 animal model Methods 0.000 title claims abstract description 8
- 230000001939 inductive effect Effects 0.000 title claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 4
- 241001465754 Metazoa Species 0.000 claims description 12
- VSFNAZLYGOOSEY-UHFFFAOYSA-N Imidazolylpropionic acid Natural products OC(=O)CCN1C=CN=C1 VSFNAZLYGOOSEY-UHFFFAOYSA-N 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000002029 Claudin Human genes 0.000 description 3
- 108050009302 Claudin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101000834245 Danio rerio Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 108010046926 intraovarian peptides Proteins 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用。
Description
本申请是申请号为2022103056198、申请日为2022年3月25日、发明名称为“咪唑丙酸作为生物标志物用于预测溃疡性结肠炎的应用以及成套用具”的申请的分案申请。
技术领域
本发明涉及诊断领域，更具体地涉及咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用。
背景技术
溃疡性结肠炎(UC)是一种局限于结肠和直肠粘膜及黏膜下层的慢性炎症性疾病，其主要症状包括腹痛、腹泻、便血、发热、以及体重下降，具有病程长，症状反复难愈的特点。长期患有UC是导致结肠癌症的危险因素之一。
人体肠道中定植着大量的微生物，它们参与食物中氨基酸等营养物质的代谢与吸收。其代谢产生的小分子物质通过吸收进入宿主体内，与多种信号通路相互作用，影响肠道生理状态的稳态。组氨酸是大量存在于肉类食物中的人体必须氨基酸，其被大肠中丰富的肠道菌消化代谢，产生一种独特的肠菌代谢物—咪唑丙酸(Imidazolepropionate，IMP)。已有报道指出，咪唑丙酸在人体血液中含量升高与饮食引起的代谢性疾病的发生密切相关(例如，参见非专利文献1)。然而，目前尚未有研究报道咪唑丙酸对UC的发生和发展有何影响。
现有技术文献
非专利文献1：Koh,A.,et al.,Microbially Produced ImidazolePropionateImpairs Insulin Signaling through mTORC1.Cell,2018.
175(4):p.947-961.
发明内容
针对上述问题，本申请人进行了深入研究，结果，动物实验证实，咪唑丙酸可引起小鼠体重减轻、疾病活动指数(disease activityindex，DAI)增加、炎症因子表达增加、粘膜组织损伤、肠屏障通透性增加等结肠炎症状，提示IMP含量增加可能是引发溃疡性结肠炎的危险因素，为开发IMP作为UC的一个早期诊断标记物提供科学依据，以便可以提前进行干预和治疗。
本发明提供以下方面的内容：
1.咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用。
2.根据上述项目1所述的应用，其中，所述动物为小鼠。
3.根据上述项目1或2所述的应用，其中，所述咪唑丙酸的给药剂量为100mg/kg动物。
4.根据上述项目1或2所述的应用，其中，给药方式为直肠内给药。
附图说明
图1A至图1E是显示IMP对C57BL/6小鼠结肠的影响的图。其中，图1A显示的是IMP处理对小鼠体重和DAI(疾病活动指数)的影响；图1B显示的是IMP处理对结肠通透性的影响；图1C显示的是IMP处理对结肠粘膜结构的影响；图1D显示的是IMP处理后结肠紧密连接蛋白表达的变化；图1E显示的是IMP处理后结肠组织中炎症因子表达变化。*表示与正常组相比，p<0.05；**表示与正常组相比，p<0.01；***表示与正常组相比，p<0.001。
具体实施方式
下面结合具体实施例对本发明所述的技术方案和有益效果做进一步的说明。
IMP对C57BL/6小鼠结肠的影响
(i)动物饲养及处理
20只健康雄性C57BL/6小鼠(北京维通利华实验动物技术有限公司)适应性喂养一周后，随机分为正常组和IMP给药组，每组10只。对于IMP给药组小鼠，采用异氟烷吸入的方式麻醉，用石蜡油润滑灌注针，由肛门插入约2-3cm，缓慢推入100μl IMP(100mg/kg)溶液。每日早晚各给药一次，持续5天。第6天，避光灌胃给予小鼠以FD-4(600mg/kg)，4h后，眼内眦取血，颈椎脱臼处死小鼠，分离结肠，用生理盐水冲洗后于液氮速冻，-80℃冰箱保存。
实验期间每日称量记录小鼠体重，观察小鼠活动情况、精神状态等，记录小鼠粪便隐血以及粪便形态，统计小鼠疾病活动指数。小鼠血清于激发波长480nm、发射波长520nm下使用SpectraMax M5进行荧光测定。取近盲肠端1cm结肠组织，生理盐水洗净后于4％多聚甲醛中固定，石蜡包埋，参照文献[1]报道的方法进行H&E染色及AB-PAS染色。
所有动物实验都得到了天津中医药大学科学技术委员会和动物使用与护理委员会的批准。
参考文献[1]：Y Zhao,Luan H,Gao H,et al.Gegen Qinliandecoctionmaintains colonic mucosal homeostasis in acute/chronic ulcerativecolitis viabidirectionally modulating dysregulated Notch signaling[J].Phytomedicine,2020,68:153182.
(ii)q-PCR检测结肠组织中炎症因子表达
参照文献[2,3]报道的方法，对结肠组织中的炎症因子进行检测，具体方法为：称取30mg结肠组织，加入1ml TRIzol试剂(北京全式金生物技术股份有限公司)，提取总RNA，用NanoDrop 2000测定RNA浓度。采用High-Capacity cDNA Reverse Transcription Kit试剂盒(康为世纪生物科技股份有限公司)进行逆转录，合成cDNA。采用SYBR Green PCRMaster Mix试剂盒(康为世纪生物科技股份有限公司)及Applied Biosystems 7500Real-time PCR System进行PCR反应扩增，以GAPDH作为内参。
采用的引物序列为
NF-κB:Forward CCTCTCTCGTCTTCCTCCAC；Reverse GTTGCGGAAGGATGTCTCC；
iNOS:Forward GGGTCACAACTTTACAGGGAGT；Reverse GAGTGAACAAGACCCAAGCG；
IL6:Forward GTCCTTCCTACCCCAATTTCCA；Reverse TAACGCACTAGGTTTGCCGA；
GAPDH:Forward GGTGAAGGTCGGTGTGAACG；Reverse CTCGCTCCTGGAAGATGGTG。
反应条件为：95℃预变性10min，95℃变性15s，60℃退火60s，72℃延伸5min，共40个循环。应用2-ΔΔCT方法计算各基因相对含量，每组实验n＝6。
参考文献[2]：Vivinus-Nébot M,Frin-Mathy G,Bzioueche H et al.Functionalbowel symptoms in quiescent inflammatory bowel diseases:role of epithelialbarrier disruption and low-grade inflammation.[J].Gut,2014,63:744-52.
参考文献[3]：Gu Guangli,Lv Xiaodan,Liu Gengfeng et al.Tnfaip6 Secretedby Bone Marrow-Derived Mesenchymal Stem Cells Attenuates TNBS-Induced Colitisby Modulating Follicular Helper T Cells and Follicular Regulatory T CellsBalance in Mice.[J].Front Pharmacol,2021,12:734040.
(iii)Western blot检测结肠组织中紧密连接蛋白表达
参照文献[4]报道的方法，对结肠组织中紧密连接蛋白进行检测，具体方法为：称取30mg结肠组织，加入300μl RIPA蛋白裂解液，提取蛋白。采用BCA(Bicinchoninic Acid)蛋白定量法检测样品蛋白含量。采用SDS-PAGE电泳法，按照预定程序(80V，50min；110V，50min)进行凝胶电泳，电泳结束后，将蛋白转移至PVDF膜。5％脱脂奶粉封闭后，于4℃孵育一抗过夜(Occludin 1:5000；ZO-11:1000；β-actin 1:1000)。二抗(HRP山羊抗兔多克隆抗体1:10000)孵育1h后，用化学发光法检测目标蛋白的表达。
参考文献[4]：Yang Mingyue,Jia Wenxiu,Wang Dong et al.Effects andMechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier inDSS-Induced Colitis.[J].Dig Dis Sci,2019,64:1844-1856.
统计学处理
实验结果采用SPSS20.0统计学软件分析，计量资料以均数±标准差(X±SEM)表示，样本比较采用独立样本t检验分析，p值小于0.05判定为样本间具有显著差异。
实验结果
图1A至图1E的结果显示，IMP处理可引起小鼠结肠炎样症状，包括体重下降、DAI指数增加、结肠通透性增加、以及肠粘膜结构损坏伴中性粒细胞浸润及杯状细胞减少。另外，IMP导致结肠组织中紧密连接蛋白(Occludin、ZO-1)显著减少，并且炎症相关因子NF-κB、iNOS和IL6表达显著增加。动物实验结果表明，IMP可引起结肠炎症及肠屏障损坏，可作为溃疡性结肠炎的一个早期诊断标记物。并且，动物实验结果也表明IMP可以用作诱导溃疡性结肠炎动物模型的造模剂。
以上所述的实施例只是本发明的一种较佳的方案，并非对本发明作任何形式上的限制，在不超过权利要求所记载的技术方案的前提下，还可以有其他的变形。可以理解的是，以上实施例仅仅是为了说明本公开的原理而采用的示例性实施例，然而本公开并不局限于此。对于本领域普通技术人员而言，在不脱离本公开的精神和实质的情况下，可以做出各种变型和改进，这些变型和改进也视为本公开的保护范围。
Claims (4)
1.咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用。
2.根据权利要求1所述的应用，其中，所述动物为小鼠。
3.根据权利要求1或2所述的应用，其中，所述咪唑丙酸的给药剂量为100mg/kg动物。
4.根据权利要求1或2所述的应用，其中，给药方式为直肠内给药。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311848219.2A CN117598247A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311848219.2A CN117598247A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 |
| CN202210305619.8A CN114689747A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸作为生物标志物用于预测溃疡性结肠炎的应用以及成套用具 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210305619.8A Division CN114689747A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸作为生物标志物用于预测溃疡性结肠炎的应用以及成套用具 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117598247A true CN117598247A (zh) | 2024-02-27 |
Family
ID=82138816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311848219.2A Pending CN117598247A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 |
| CN202210305619.8A Pending CN114689747A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸作为生物标志物用于预测溃疡性结肠炎的应用以及成套用具 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210305619.8A Pending CN114689747A (zh) | 2022-03-25 | 2022-03-25 | 咪唑丙酸作为生物标志物用于预测溃疡性结肠炎的应用以及成套用具 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN117598247A (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6679309B2 (ja) * | 2012-08-29 | 2020-04-15 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症スペクトラム障害の診断および処置 |
| EP3850359A4 (en) * | 2018-09-11 | 2022-11-02 | Metabolon Inc. | ASSAY METHOD BY MASS SPECTROMETRY FOR THE DETECTION AND QUANTIFICATION OF MICROBIOTA-BOUND METABOLITES |
| US20230181531A1 (en) * | 2020-02-28 | 2023-06-15 | Academisch Medisch Centrum | Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease |
-
2022
- 2022-03-25 CN CN202311848219.2A patent/CN117598247A/zh active Pending
- 2022-03-25 CN CN202210305619.8A patent/CN114689747A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114689747A (zh) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pai et al. | Deoxycholic acid activates β-catenin signaling pathway and increases colon cell cancer growth and invasiveness | |
| Clinton et al. | Effects of ammonium acetate and sodium cholate on N-methyl-N′-nitro-N-nitrosoguanidine-induced colon carcinogenesis of rats | |
| Ma et al. | Defective dietary fat processing in transgenic mice lacking aquaporin-1 water channels | |
| JP2021063088A (ja) | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 | |
| AU2013266086B2 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | |
| Vegge et al. | Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates | |
| TW201642869A (zh) | 組合療法醫藥組合物 | |
| Li et al. | Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts | |
| Feng et al. | Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease | |
| KR20170049606A (ko) | 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합 | |
| Kuang et al. | Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis | |
| CN104822378A (zh) | 作为糖尿病的生物标志物的cmpf和相关方法 | |
| Lyu et al. | Scoparone alleviates Ang II‐induced pathological myocardial hypertrophy in mice by inhibiting oxidative stress | |
| RU2587053C2 (ru) | Комбинированная терапия и способ оценки невосприимчивости к лечению | |
| Ma et al. | Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathy mice | |
| Alhagamhmad et al. | Advancing nutritional therapy: A novel polymeric formulation attenuates intestinal inflammation in a murine colitis model and suppresses pro-inflammatory cytokine production in ex-vivo cultured inflamed colonic biopsies | |
| Zhang et al. | Oleic acid and insulin as key characteristics of T2D promote colorectal cancer deterioration in xenograft mice revealed by functional metabolomics | |
| CN113424795A (zh) | 一种急性胰腺炎动物模型的构建方法和用途 | |
| Tahara | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH | |
| TWI245643B (en) | Composition for selective cancer chemotherapy | |
| Tiwari et al. | Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats | |
| CN117598247A (zh) | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 | |
| Bishop et al. | Effect of firocoxib and flunixin meglumine on large colon mural thickness of healthy horses | |
| US20230405078A1 (en) | Detection and treatment of intestinal fibrosis | |
| Fuller et al. | Oral combined contraceptives induce liver mitochondrial reactive oxygen species and whole‐body metabolic adaptations in female mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |